[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002074288A2 - Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide - Google Patents

Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide Download PDF

Info

Publication number
WO2002074288A2
WO2002074288A2 PCT/GB2002/001220 GB0201220W WO02074288A2 WO 2002074288 A2 WO2002074288 A2 WO 2002074288A2 GB 0201220 W GB0201220 W GB 0201220W WO 02074288 A2 WO02074288 A2 WO 02074288A2
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
sexual dysfunction
ssri
compound
selective serotonin
Prior art date
Application number
PCT/GB2002/001220
Other languages
French (fr)
Other versions
WO2002074288A3 (en
Inventor
John Blundell Hutchison
Original Assignee
Vernalis Research Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Limited filed Critical Vernalis Research Limited
Priority to AU2002246228A priority Critical patent/AU2002246228A1/en
Publication of WO2002074288A2 publication Critical patent/WO2002074288A2/en
Publication of WO2002074288A3 publication Critical patent/WO2002074288A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Definitions

  • the present invention relates to pharmaceutical compositions containing a 5HTTA agonist for treating and/or preventing sexual dysfunctions associated with the use of selective serotonin re-uptake inhibitors.
  • SSRIs Selective serotonin re-uptake inhibitors
  • TCAs tricyclic antidepressants
  • the non-serotonergic agent Sildenafil has been used in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors (Nurnberg, H. G.; Hensley, P. L.; Whyllo, J. Sildenafil in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors: an overview. CNS Drugs (2000), 13(5), 321-335).
  • Some of the potential treatments for sexual dysfunction are serotonergic agents, such as cyproheptadine, a 5HT 2 antagonist with antihistaminergic and adrenolytic properties.
  • This compound has been investigated in a clinical trial (Aizenberg, D.; Zemishlany, Z.; Weizman, A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin. Neuropharmacol. (1995), 18(4), 320-4).
  • a range of 5HT2 receptor ligands have been described in WO 0028993 Al (Nortran Pharmaceuticals Inc.) as being useful as pro-erectile compounds.
  • a series of oxazole derivatives have been claimed as serotonin-lA receptor agonists in US 6057340 (American Home Products Corporation, USA), and hexahydropyrazinoquinoline derivatives exhibiting serotonin 5-HTi A receptor agonist effects have been claimed in WO 9623789 Al (Sankyo Co., Ltd., Japan).
  • Some ring-substituted 2-amino- 1,2,3 ,4-tetrahydro- naphthalenes and 3-aminochromans have been claimed as selective agonists at the 5-HT IA receptor in EP 385658 (Lilly, Eli and Co., USA).
  • a series of tetrahydrobenz[cd]indole-6- carboxamides are claimed for the prevention of emesis and treatment sexual dysfunction.
  • the present invention provides the use of an effective amount of compound 1 (also referred to herein as a SHT A agonist) to prepare a medicament for treatment of sexual dysfunction in a patient (preferably a human) who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor (SSRI).
  • SHT A agonist selective serotonin re-uptake inhibitor
  • Compound 1 is (4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd3indole ⁇ 6-carboxamide, also known as (R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide:
  • the present invention further provides a method of treatment of sexual dysfunction in a patient (preferably a human) who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor, said method including administering to a patient in need of such treatment an effective amount of compound 1 (also referred to herein as a 5HT IA agonist).
  • a patient preferably a human
  • a selective serotonin re-uptake inhibitor comprising to a patient in need of such treatment an effective amount of compound 1 (also referred to herein as a 5HT IA agonist).
  • the present invention further provides a composition comprising compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs), preferably selected from those set out in any of claims 3 to 8.
  • SSRIs selective serotonin re-uptake inhibitors
  • the present invention further provides the use of compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs) in the manufacture of a medicament for the treatment of depression without inducing sexual dysfunction.
  • the present invention further provides a method of treatment of depression without inducing sexual dysfunction, said treatment including administering to a patient in need of such treatment an effective amount of compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs).
  • Compound (1) and the one or more SSRIs may be present in the same formulation or may be present in different formulations for administration sequentially or simultaneously.
  • sexual dysfunction means any disorder related to the erectile response in male mammals and the sexual drive and sexual (both arousal and orgasmic) reflexes in male or female mammals. Accordingly, the term “sexual dysfunction” includes male sexual dysfunction including impotence (also known in the art and referred to herein as "male erectile dysfunction"), retarded ejaculation and anorgasm, and female sexual dysfunction including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, . pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation and diminished clitoral orgasm.
  • impotence also known in the art and referred to herein as "male erectile dysfunction”
  • female sexual dysfunction including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, . pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation,
  • Reference to compound 1 herein shall be understood to include all active forms thereof, including the free form thereof; all pharmaceutically acceptable acid addition salts thereof; all prodrugs, polymorphs, hydrates, solvates and stereoisomers (e.g. diastereomers and enantiomers) thereof; and active metabolites thereof.
  • pharmaceutically acceptable acid addition salts refers to the acid addition salts of the compounds of which are substantially non-toxic to living organisms.
  • Typical pharmaceutically acceptable acid addition salts include those salts prepared by reaction of the free base form of the compound with a pharmaceutically acceptable mineral or organic acid.
  • mineral or organic acids commonly employed to form such salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric and phosphoric acid, as well as organic acids such as paratoluenesulfonic, methane-sulfonic, hippuric, oxalic, parabromophenylsulfonic, carbonic, succinic, citric, benzoic, acetic, and related inorganic and organic acids.
  • inorganic acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric and phosphoric acid
  • organic acids such as paratoluenesulfonic, methane-sulfonic, hippuric, oxalic, parabromophenylsulfonic, carbonic, succinic, citric, benzoic, acetic, and related inorganic and organic acids.
  • Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydro-genphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, hydrochloride, hydrobromide, hydroiodide, acetate, nitrate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephathalate, sulfonate, xylenesulfonate,
  • a particularly preferred pharmaceutically acceptable acid addition salt for use in the present invention is the hippurate salt.
  • Such salt form, and processes for preparing same, is disclosed in European Patent Application 444,852, the teachings of which are hereby incorporated by reference.
  • the compound 1 is synthesised as described (Carr, M. A.; Creviston, P. E.; Hutchison, D. R.; Kennedy, J. H.; Khau, N. N.; Kress, T. J.; Leanna, M. R.; Marshall, J. D.; Martinelli, M. J.; Peterson, B. C; Varie, D. L.; Wepsiec, J. P. J. Org. Chem. (1997), 62, 8640-8653).
  • Compound 1 has been described as a selective serotonin 1A agonist (Foreman, M. M.; Fuller, R. W.; Leander, J. D; Benvenga, M. J.; Wong, D.
  • Compound 1 facilitated sexual behaviour in male rats by decreasing ejaculatory latency and the number of mounts required for ejaculation (Figure 1). These findings indicate that Compound 1 can lower the latency and stimulus requirements for this sexual reflex as a part of its capacity to improve all aspects of the male rat sexual response.
  • Compound 1 also induced increases in the efficiency and rate of copulation ( Figure 2).
  • the increased copulatory efficiency suggests that Compound 1 improved the capacity of these rats to achieve erections sufficient for intromission.
  • the increased copulatory rate indicates that Compound 1 elevated the sexual drive, thereby providing utility in treating disorders related to erectile response, sexual drive, and orgasmic reflexes.
  • the present invention utilizes pharmaceutical compositions.
  • one or more active ingredients will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container.
  • a carrier which may be in the form of a capsule, sachet, paper or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
  • Suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline solution, syrup, methylcellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate and mineral oil.
  • the formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents.
  • the compositions may be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
  • compositions are formulated, preferably in a unit dosage form, such that each dosage contains from about 50 ⁇ m to about 500 mg, more usually about 50 ⁇ m to about 30 mg, of the active ingredient.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic or prophylactic effect, in association with one or more suitable pharmaceutical diluents, excipients or carriers.
  • the compound employed in the present invention is effective over a wide dosage range for preventing or treating sexual dysfunction.
  • the term “effective amount” refers to a dosage range of from about 0.5 ⁇ m to about 10 mg/kg of body weight per day.
  • the range of about 0.5 ⁇ m to about 1 mg/kg, in single or divided doses is preferred.
  • the amount of compound actually administered will be determined by a physician, in light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, whether prophylactic or therapeutic effect is desired, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and, therefore, the above dosage ranges are not intended to limit the scope of the invention in any way.
  • formulation examples may employ as active ingredients compounds 1 or any of its pharmaceutically acceptable salts.
  • the examples are illustrative only and are not intended to limit the scope of the invention in any way.
  • Hard gelatin capsules suitable for preventing emesis are prepared using the following ingredients:
  • the above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.
  • a tablet suitable for preventing emesis is prepared using the ingredients below: Quantity (mg/tablet)
  • the components are blended and compressed to form tablets each weighing 665 mg.
  • An aerosol solution suitable for treating sexual dysfunction is prepared containing the following components: Weight
  • the active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30 DEG C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. Naive units are then fitted to the container.
  • Tablets suitable for treating sexual dysfunction each containing 60 mg of active ingredient are made up as follows:
  • Microcrystalline cellulose 35 mg
  • the active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
  • the solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve.
  • the granules so produced are dried at 50-60 DEG C and passed through a No. 18 mesh U.S. sieve.
  • the sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed by a tablet machine to yield tablets each weighing 150 mg.
  • Capsules suitable for preventing emesis are made as follows:
  • the active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
  • Suppositories suitable for treating sexual dysfunction are made as follows:
  • the active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.
  • Example 7 Suspensions suitable for preventing emesis, each containing 50 mg of medicament per 5 ml dose, are made as follows:
  • the medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste.
  • the benzoic acid solution, flavor and colour are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
  • Capsules suitable for use in treating sexual dysfunction are made as follows: (4R)-4-(dipropylarnino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide hippurate : 150 mg
  • Microcrystalline cellulose 164 mg
  • the active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 500 mg quantities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

The use of an effective amount of compound (I) in the manufacture of a medicament for treatment of sexual dysfunction in a patient who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor; and the use of an effective amount of compound (I) and one or more selective serotonin re-uptake inhibitor(s) in the manufacture of a medicament for the treatment of depression without inducing sexual dysfunction.

Description

CHEMICAL COMPOUNDS
The present invention relates to pharmaceutical compositions containing a 5HTTA agonist for treating and/or preventing sexual dysfunctions associated with the use of selective serotonin re-uptake inhibitors.
Selective serotonin re-uptake inhibitors (SSRIs) are acknowledged as effective and widely- used antidepressant drugs. They are better tolerated alternatives to the older tricyclic antidepressants (TCAs) for the treatment of depression (Mace, S; Taylor, D. Selective serotonin reuptake inhibitors: A review of efficacy and tolerability in depression. Expert Opin. Pharmacother. (2000), 1(5), 917-933). However, the widespread use of SSRIs has highlighted some unforeseen adverse effects associated with SSRIs, namely hyponatremia, EPSE and sexual dysfunction.
Even though adverse effects associated with antidepressant drug therapy rarely cause significant morbidity or mortality, the successful management of patients with depression requires recognition of potential adverse effects which include the discontinuation of this otherwise effective antidepressant therapy (Settle, E.C., Jr. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J. Clin. Psychiatry (1998), 59(Suppl. 16), 25-30).
Adverse effects related to sexual function are common, esp. with TCAs, SSRIs, and venlafaxine and have been documented with individual drugs (Kennedy, S. H.; Eisfeld, B. S.; Dickens, S. E.; Bacchiochi, J. R.; Bagby, R. M. J. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. Clin. Psychiatry (2000), 61(4), 276-281). Sexual dysfunction (SD) often leads to non- compliance and self-discontinuation of therapy; the increasing use of SSRIs has meant that the latter side-effect has come into sharper focus (Sargent, P. A.; Goodwin, G. M., SSRIs and sexual function, Neurosci. Intell. Unit (1999), 6 (Selective Serotonin Reuptake Inhibitors (SSRIs)), 81-94).
As many as half of patients treated with selective serotonin reuptake inhibitors report delayed orgasm (ejaculation), and virtually all patients treated with clomipramine experience anorgasmia. Although depressed patients do care about their sexual function, they may be reluctant, for fear of embarrassment, to report SD spontaneously to their physicians. SD is probably underreported and may result in covert noncompliance and attendant relapse into depression. As a result of this potentially dangerous scenario, new treatments are being sought for antidepressant-induced sexual dysfunction (Rothschild, A. J. New directions in the treatment of antidepressant-induced sexual dysfunction. Clin. Ther. (2000), 22(Suppl. A), A42-A61.
The non-serotonergic agent Sildenafil has been used in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors (Nurnberg, H. G.; Hensley, P. L.; Lauriello, J. Sildenafil in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors: an overview. CNS Drugs (2000), 13(5), 321-335).
Some of the potential treatments for sexual dysfunction are serotonergic agents, such as cyproheptadine, a 5HT2 antagonist with antihistaminergic and adrenolytic properties. This compound has been investigated in a clinical trial (Aizenberg, D.; Zemishlany, Z.; Weizman, A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin. Neuropharmacol. (1995), 18(4), 320-4). A range of 5HT2 receptor ligands have been described in WO 0028993 Al (Nortran Pharmaceuticals Inc.) as being useful as pro-erectile compounds.
A series of oxazole derivatives have been claimed as serotonin-lA receptor agonists in US 6057340 (American Home Products Corporation, USA), and hexahydropyrazinoquinoline derivatives exhibiting serotonin 5-HTiA receptor agonist effects have been claimed in WO 9623789 Al (Sankyo Co., Ltd., Japan). Some ring-substituted 2-amino- 1,2,3 ,4-tetrahydro- naphthalenes and 3-aminochromans have been claimed as selective agonists at the 5-HTIA receptor in EP 385658 (Lilly, Eli and Co., USA).
In EP 0633023 (Lilly, Eli and Co., USA), a series of tetrahydrobenz[cd]indole-6- carboxamides are claimed for the prevention of emesis and treatment sexual dysfunction. The present invention provides the use of an effective amount of compound 1 (also referred to herein as a SHT A agonist) to prepare a medicament for treatment of sexual dysfunction in a patient (preferably a human) who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor (SSRI).
Compound 1 is (4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd3indole~6-carboxamide, also known as (R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide:
Figure imgf000004_0001
Compound 1
The present invention further provides a method of treatment of sexual dysfunction in a patient (preferably a human) who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor, said method including administering to a patient in need of such treatment an effective amount of compound 1 (also referred to herein as a 5HTIA agonist).
The present invention further provides a composition comprising compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs), preferably selected from those set out in any of claims 3 to 8.
The present invention further provides the use of compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs) in the manufacture of a medicament for the treatment of depression without inducing sexual dysfunction. The present invention further provides a method of treatment of depression without inducing sexual dysfunction, said treatment including administering to a patient in need of such treatment an effective amount of compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs). Compound (1) and the one or more SSRIs may be present in the same formulation or may be present in different formulations for administration sequentially or simultaneously.
The term "sexual dysfunction", as used herein, means any disorder related to the erectile response in male mammals and the sexual drive and sexual (both arousal and orgasmic) reflexes in male or female mammals. Accordingly, the term "sexual dysfunction" includes male sexual dysfunction including impotence (also known in the art and referred to herein as "male erectile dysfunction"), retarded ejaculation and anorgasm, and female sexual dysfunction including the vasculogenic symptoms of delayed vaginal engorgement, diminished vaginal lubrication, . pain or discomfort with intercourse (dyspareunia), diminished vaginal sensation, diminished vaginal orgasm, diminished clitoral sensation and diminished clitoral orgasm.
Reference to compound 1 herein shall be understood to include all active forms thereof, including the free form thereof; all pharmaceutically acceptable acid addition salts thereof; all prodrugs, polymorphs, hydrates, solvates and stereoisomers (e.g. diastereomers and enantiomers) thereof; and active metabolites thereof.
The term "pharmaceutically acceptable acid addition salts", as used herein, refers to the acid addition salts of the compounds of which are substantially non-toxic to living organisms. Typical pharmaceutically acceptable acid addition salts include those salts prepared by reaction of the free base form of the compound with a pharmaceutically acceptable mineral or organic acid. Pharmaceutically acceptable mineral or organic acids commonly employed to form such salts include inorganic acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric and phosphoric acid, as well as organic acids such as paratoluenesulfonic, methane-sulfonic, hippuric, oxalic, parabromophenylsulfonic, carbonic, succinic, citric, benzoic, acetic, and related inorganic and organic acids. Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydro-genphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, hydrochloride, hydrobromide, hydroiodide, acetate, nitrate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, butyne-l,4-dioate, hexyne-l,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate, terephathalate, sulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, beta -hydroxybutyrate, glycollate, tartrate, methanesulfonate, propanesulfonate, naphthalene-2-sulfonate, p- tolutenesulfonate, mandelate, hippurate, and like salts.
A particularly preferred pharmaceutically acceptable acid addition salt for use in the present invention is the hippurate salt. Such salt form, and processes for preparing same, is disclosed in European Patent Application 444,852, the teachings of which are hereby incorporated by reference.
Experimental procedures
The compound 1 is synthesised as described (Carr, M. A.; Creviston, P. E.; Hutchison, D. R.; Kennedy, J. H.; Khau, N. N.; Kress, T. J.; Leanna, M. R.; Marshall, J. D.; Martinelli, M. J.; Peterson, B. C; Varie, D. L.; Wepsiec, J. P. J. Org. Chem. (1997), 62, 8640-8653). Compound 1 has been described as a selective serotonin 1A agonist (Foreman, M. M.; Fuller, R. W.; Leander, J. D; Benvenga, M. J.; Wong, D. T.; Nelson, D. L.; Calligaro, D. O.; Swanson, S. P.; Lucot, J. B.; Flaugh, M. E. J. Pharmacol. Exp. Ther. (1993), 267, 58- 71).
Animal Models of Sexual Function
Sexual behaviour has been studied in rats following single doses of Compound 1. Latency and stimulus threshold for ejaculation were reduced in rats. The males demonstrated increased sexual activity at relatively low doses (1.0 to 100 μg/kg, s.c.)
Compound 1 facilitated sexual behaviour in male rats by decreasing ejaculatory latency and the number of mounts required for ejaculation (Figure 1). These findings indicate that Compound 1 can lower the latency and stimulus requirements for this sexual reflex as a part of its capacity to improve all aspects of the male rat sexual response.
Compound 1 also induced increases in the efficiency and rate of copulation (Figure 2). The increased copulatory efficiency (number of intromissions/total number of mounts) suggests that Compound 1 improved the capacity of these rats to achieve erections sufficient for intromission. The increased copulatory rate indicates that Compound 1 elevated the sexual drive, thereby providing utility in treating disorders related to erectile response, sexual drive, and orgasmic reflexes.
As mentioned above, the present invention utilizes pharmaceutical compositions. In making these compositions, one or more active ingredients will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing for example up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, saline solution, syrup, methylcellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide rapid, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The compositions are formulated, preferably in a unit dosage form, such that each dosage contains from about 50 μm to about 500 mg, more usually about 50 μm to about 30 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic or prophylactic effect, in association with one or more suitable pharmaceutical diluents, excipients or carriers. The compound employed in the present invention is effective over a wide dosage range for preventing or treating sexual dysfunction. Thus, as used herein, the term "effective amount" refers to a dosage range of from about 0.5 μm to about 10 mg/kg of body weight per day. In the treatment of adult humans, the range of about 0.5 μm to about 1 mg/kg, in single or divided doses, is preferred. However, it will be understood that the amount of compound actually administered will be determined by a physician, in light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, whether prophylactic or therapeutic effect is desired, the chosen route of administration, the age, weight, and response of the individual patient, and the severity of the patient's symptoms, and, therefore, the above dosage ranges are not intended to limit the scope of the invention in any way.
The following formulation examples may employ as active ingredients compounds 1 or any of its pharmaceutically acceptable salts. The examples are illustrative only and are not intended to limit the scope of the invention in any way.
Example 1
Hard gelatin capsules suitable for preventing emesis are prepared using the following ingredients:
Quantity (mg/capsule)
(4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide hippurate: 250
Starch dried : 200
Magnesium stearate : 10
The above ingredients are mixed and filled into hard gelatin capsules in 460 mg quantities.
Example 2
A tablet suitable for preventing emesis is prepared using the ingredients below: Quantity (mg/tablet)
(4R)-4-(dipropylamino)-l ,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide : 250 Cellulose, microcrystalline : 400 Silicon dioxide : 10 Stearic acid : 5
The components are blended and compressed to form tablets each weighing 665 mg.
Example 3
An aerosol solution suitable for treating sexual dysfunction is prepared containing the following components: Weight
(4R)-4-(dipropylamino)-l ,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide : 0.25 Ethanol : 29.75
-Propellant 22 (Chlorodifluoromethane) : 70.00 .
The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30 DEG C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. Naive units are then fitted to the container.
Example 4
Tablets suitable for treating sexual dysfunction, each containing 60 mg of active ingredient are made up as follows:
(4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide : 60 mg
Starch 45 : mg
Microcrystalline cellulose : 35 mg
Polyvinylpyrrolidone (as 10% solution in water) : 4 mg Sodium carboxymethyl starch : 4.5 mg
Magnesium stearate : 0.5 mg
Talc : 1 mg
Total : 150 mg
The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders which are then passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50-60 DEG C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed by a tablet machine to yield tablets each weighing 150 mg.
Example 5
Capsules suitable for preventing emesis, each containing 80 mg of medicament, are made as follows:
(4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide : 80 mg Starch : 59 mg Microcrystalline cellulose : 59 mg Magnesium stearate : 2 mg Total : 200 mg
The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Example 6
Suppositories suitable for treating sexual dysfunction, each containing 225 mg of active ingredient, are made as follows:
(4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide : 225 mg Saturated fatty acid glycerides to 2,000 mg
The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.
Example 7 Suspensions suitable for preventing emesis, each containing 50 mg of medicament per 5 ml dose, are made as follows:
(4R)-4-(dipropylamino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide : 50 mg Sodium carboxymethyl cellulose : 50 mg Syrup : 1.25 mg Benzoic acid solution : 0.10 ml Flavour q.v. Colour q.v. Purified water to 5 ml
The medicament is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and colour are diluted with some of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Example 8
Capsules suitable for use in treating sexual dysfunction, each containing 150 mg of medicament, are made as follows: (4R)-4-(dipropylarnino)-l,3,4,5-tetrahydrobenz[cd]indole-6-carboxamide hippurate : 150 mg
Starch : 164 mg
Microcrystalline cellulose : 164 mg
Magnesium stearate : 22 mg Total : 500 mg
The active ingredient, cellulose, starch and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 500 mg quantities.

Claims

Claims
1. The use of an effective amount of compound 1
Figure imgf000012_0001
(1) to prepare a medicament for treatment of sexual dysfunction in a patient who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor (SSRI).
2. A method of treatment of sexual dysfunction in a patient who is undergoing or is about to undergo treatment with a selective serotonin re-uptake inhibitor (SSRI), said method including administering to a patient in need of such treatment an effective amount of compound 1.
3. Use of an effective amount of compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs) in the manufacture of a medicament for the treatment of depression without inducing sexual dysfunction.
4. A method of treatment of depression without inducing sexual dysfunction, said treatment including administering to a patient in need of such treatment an effective amount of compound (1) and one or more selective serotonin re-uptake inhibitors (SSRIs).
5. The use of claims 1 or 3 or the method of claims 2 or 4 where the SSRI is citalopram.
6. The use of claims 1 or 3 or the method of claims 2 or 4 where the SSRI is fluoxetine.
7. The use of claims 1 or 3 or the method of claims 2 or 4 where the SSRI is fluvoxamine.
8. The use of claims 1 or 3 or the method of claims 2 or 4 where the SSRI is paroxetine.
9. The use of claims 1 or 3 or the method of claims 2 or 4 where the SSRI is sertraline.
10. The use of claims 1 or 3 or the method of claims 2 or 4 where the SSRI is venlafaxine.
11. A composition comprising compound (1) and one or more selective serotonin reuptake inhibitors (SSRIs).
12. A composition according to claim 9 wherein the SSRI is selected from those set out in any of claims 5 to 10.
PCT/GB2002/001220 2001-03-15 2002-03-15 Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide WO2002074288A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002246228A AU2002246228A1 (en) 2001-03-15 2002-03-15 Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106446.8A GB0106446D0 (en) 2001-03-15 2001-03-15 Chemical compounds
GB0106446.8 2001-03-15

Publications (2)

Publication Number Publication Date
WO2002074288A2 true WO2002074288A2 (en) 2002-09-26
WO2002074288A3 WO2002074288A3 (en) 2003-02-27

Family

ID=9910774

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/001220 WO2002074288A2 (en) 2001-03-15 2002-03-15 Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide

Country Status (3)

Country Link
AU (1) AU2002246228A1 (en)
GB (1) GB0106446D0 (en)
WO (1) WO2002074288A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US9468639B2 (en) 2001-10-20 2016-10-18 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US9546141B2 (en) 2008-12-15 2017-01-17 Sprout Pharmaceuticals, Inc. Salts
US9730927B2 (en) 2005-08-03 2017-08-15 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US9763936B2 (en) 2006-06-30 2017-09-19 Sprout Pharmaceuticals, Inc. Flibanserin for the treatment of urinary incontinence and related diseases
US10166230B2 (en) 2007-09-12 2019-01-01 Sprout Pharmaceuticals Inc. Treatment of vasomotor symptoms
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109872A (en) * 1993-06-10 2000-12-06 Lilly Co Eli Tetrahydrobenz ¬CD¾ indole-6-carboxamides for use in preventing emesis and pharmaceutical compositions comprising same

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782403B2 (en) 2001-10-20 2017-10-10 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US9468639B2 (en) 2001-10-20 2016-10-18 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US11058683B2 (en) 2001-10-20 2021-07-13 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US10335407B2 (en) 2005-08-03 2019-07-02 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US9730927B2 (en) 2005-08-03 2017-08-15 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US10874668B2 (en) 2005-08-03 2020-12-29 Sprout Pharmaceuticals, Inc. Use of Flibanserin in the treatment of obesity
US10004731B2 (en) 2006-06-30 2018-06-26 Sprout Pharmaceuticals, Inc. Flibanserin for the treatment of urinary incontinence and related diseases
US9763936B2 (en) 2006-06-30 2017-09-19 Sprout Pharmaceuticals, Inc. Flibanserin for the treatment of urinary incontinence and related diseases
US10166230B2 (en) 2007-09-12 2019-01-01 Sprout Pharmaceuticals Inc. Treatment of vasomotor symptoms
US9546141B2 (en) 2008-12-15 2017-01-17 Sprout Pharmaceuticals, Inc. Salts

Also Published As

Publication number Publication date
GB0106446D0 (en) 2001-05-02
WO2002074288A3 (en) 2003-02-27
AU2002246228A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
JP4925074B2 (en) A pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
AU761510B2 (en) Combination therapy for treatment of refractory depression
BRPI0609952A2 (en) Methods to Modulate Bladder Function
US6960577B2 (en) Combination therapy for treatment of refractory depression
US5703112A (en) Method of preventing emesis using tetrahydrobenz CD!indole-6-carbonxamides
WO2002074288A2 (en) Treatment and prevention of sexual dysfunction resulting from ssri-therapy by using a tetrahydrobenz cd indole-6-carboxamide
WO1997006792A1 (en) Potentiation of serotonin response
NZ537521A (en) Use of reboxetine for the treatment of hot flashes
AU4064093A (en) Pharmaceutical compositions of alkylsulphonamides 5HT1 agonists for rectal administration
KR20120117936A (en) Use of agomelatine in obtaining medicaments intended for the treatment of obsessive-compulsive disorder(ocd)
EP2089022A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation
US6011054A (en) Method for treating depression, obsessive compulsive disorder, and anxiety with N--acetyl serotonin
NZ546630A (en) Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders
AU719501B2 (en) Melatonin agonists for treating benign prostatic hyperplasia
CA2386287A1 (en) Combination treatment for depression and anxiety
JP4677705B2 (en) Headache prevention and / or treatment
WO2024226995A1 (en) Compositions and methods for treating post-traumatic stress disorder
WO2002056869A2 (en) Method for treating sexual disorders
HK1013796A (en) Preventing emesis and treating sexual dysfunction using tetrahydrobenz cd indole-6-carboxamides
CA2508477A1 (en) Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz ¬cd| indole-6-carboxamides
ITMI960114A1 (en) USE OF HYDROISOKINOLINE DERIVATIVES
HK1119055A (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP